Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Arpin

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Lung Cancer (Amsterdam, Netherlands)|June 1, 1996
The limits of chemotherapy dose intensification using granulocyte colony stimulating factor alone in extensive small cell lung cancerV Trillet-Lenoir, P Soler, D Arpin, et al.
Bulletin Du Cancer|December 1, 1993
[Value of C-reactive protein determination in small cell lung cancer]D Arpin, V Trillet-Lenoir, C Lasset, et al.
Revue Des Maladies Respiratoires|May 31, 2015
[Tumor-bronchial actinomycosis simulating a recurrence of lung cancer 14 years after initial treatment: A case report]L Folliet, T Perpoint, J-C Pignat, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Combination IL-2 and cisplatinum: a promising treatment for bronchioloalveolar carcinoma?V Trillet-Lenoir, D Arpin, A Mercatello, et al.
Revue Des Maladies Respiratoires|June 16, 2022
[Systemic nocardiosis with mediastinal lymph node involvement proven by endoscopic ultrasound]S Storme, R Bricca, C M Gaillard, et al.
International Journal of Radiation Oncology, Biology, Physics|September 7, 2000
Prospective evaluation of early lung toxicity following three-dimensional conformal radiation therapy in non-small-cell lung cancer: preliminary resultsM P Sunyach, L Falchero, P Pommier, et al.
Lung Cancer (Amsterdam, Netherlands)|May 3, 2016
Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumorsT Walter, D Planchard, K Bouledrak, et al.
Targeted Oncology|August 29, 2015
Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 StudyJ B Auliac, C Fournier, C Audigier Valette, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Lung Cancer (Amsterdam, Netherlands)|June 1, 1996
The limits of chemotherapy dose intensification using granulocyte colony stimulating factor alone in extensive small cell lung cancerV Trillet-Lenoir, P Soler, D Arpin, et al.
Bulletin Du Cancer|December 1, 1993
[Value of C-reactive protein determination in small cell lung cancer]D Arpin, V Trillet-Lenoir, C Lasset, et al.
Revue Des Maladies Respiratoires|May 31, 2015
[Tumor-bronchial actinomycosis simulating a recurrence of lung cancer 14 years after initial treatment: A case report]L Folliet, T Perpoint, J-C Pignat, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Combination IL-2 and cisplatinum: a promising treatment for bronchioloalveolar carcinoma?V Trillet-Lenoir, D Arpin, A Mercatello, et al.
Revue Des Maladies Respiratoires|June 16, 2022
[Systemic nocardiosis with mediastinal lymph node involvement proven by endoscopic ultrasound]S Storme, R Bricca, C M Gaillard, et al.
International Journal of Radiation Oncology, Biology, Physics|September 7, 2000
Prospective evaluation of early lung toxicity following three-dimensional conformal radiation therapy in non-small-cell lung cancer: preliminary resultsM P Sunyach, L Falchero, P Pommier, et al.
Lung Cancer (Amsterdam, Netherlands)|May 3, 2016
Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumorsT Walter, D Planchard, K Bouledrak, et al.
Targeted Oncology|August 29, 2015
Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 StudyJ B Auliac, C Fournier, C Audigier Valette, et al.
Pageof 3